NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers

被引：0
|
作者：
Chrissie E. B. Ong
Amanda L. Patchett
Jocelyn M. Darby
Jinying Chen
Guei-Sheung Liu
A. Bruce Lyons
Gregory M. Woods
Andrew S. Flies
机构：
[1] Menzies Institute for Medical Research,Department of Ophthalmology
[2] College of Health and Medicine,Ophthalmology, Department of Surgery
[3] University of Tasmania,Tasmanian School of Medicine, College of Health and Medicine
[4] The First Affiliated Hospital of Jinan University,undefined
[5] University of Melbourne,undefined
[6] University of Tasmania,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷
关键词：
Transmissible cancer; Devil facial tumor; Allograft; MHC-I; NLRC5; Immune evasion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1973 / 1991
页数：18
相关论文
共 50 条
  • [21] NLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC Class I Gene Expression
    Meissner, Torsten B.
    Liu, Yuen-Joyce
    Lee, Kyoung-Hee
    Li, Amy
    Biswas, Amlan
    van Eggermond, Marja C. J. A.
    van den Elsen, Peter J.
    Kobayashi, Koichi S.
    JOURNAL OF IMMUNOLOGY, 2012, 188 (10): : 4951 - 4958
  • [22] NLRC5/MHC class I transactivator: A key target for immune escape by SARS-CoV-2
    Zhu, Baohui
    Ouda, Ryota
    Kasuga, Yusuke
    de Figueiredo, Paul
    Kobayashi, Koichi S.
    BIOESSAYS, 2024, 46 (04)
  • [23] Implications of Heterogeneity in Breast Tumor Cell MHC-I Expression on Immunity and Therapeutic Resistance
    Taylor, Brandie C.
    Sun, Xiaopeng
    Balko, Justin
    Gonzalez-Ericsson, Paula
    Sanders, Melinda
    CANCER RESEARCH, 2023, 83 (05)
  • [24] Pharmacological induction of MHC-I expression in tumor cells revitalizes Tcell antitumor immunity
    Yu, Qian
    Dong, Yu
    Wang, Xiaobo
    Su, Chenxuan
    Zhang, Runkai
    Xu, Wei
    Jiang, Shuai
    Dang, Yongjun
    Jiang, Wei
    JCI INSIGHT, 2024, 9 (17)
  • [25] PEDV evades MHC-I-related immunity through nsp1-mediated NLRC5 translation inhibition
    Liu, Xiang
    Zhang, Meng
    Yin, Lingdan
    Kang, Li
    Luo, Yi
    Wang, Xiaodong
    Ren, Li
    Zhang, Guozhong
    Yao, Yao
    Liu, Pinghuang
    JOURNAL OF VIROLOGY, 2024, 98 (11)
  • [26] Orientia tsutsugamushi Ank5 promotes NLRC5 cytoplasmic retention and degradation to inhibit MHC class I expression
    Adcox, Haley E.
    Hunt, Jason R.
    Allen, Paige E.
    Siff, Thomas E.
    Rodino, Kyle G.
    Ottens, Andrew K.
    Carlyon, Jason A.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [27] The N-Terminal Domain of NLRC5 Confers Transcriptional Activity for MHC Class I and II Gene Expression
    Neerincx, Andreas
    Jakobshagen, Kristin
    Utermoehlen, Olaf
    Buening, Hildegard
    Steimle, Viktor
    Kufer, Thomas A.
    JOURNAL OF IMMUNOLOGY, 2014, 193 (06): : 3090 - 3100
  • [28] NLRC5 potentiates anti-tumor CD8+T cells responses by activating interferon-β in endometrial cancer
    Zhang, Jing
    Guo, Bao
    Chen, Jia-Hua
    Liu, Xiao-Jing
    Zhang, Jun-Hui
    Zhu, Hai-Qing
    Wang, Wen-Yan
    Tang, Zhen-Hai
    Wei, Bing
    Cao, Yun-Xia
    Zhan, Lei
    TRANSLATIONAL ONCOLOGY, 2023, 36
  • [29] AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma
    Fukuda, Keitaro
    Okamura, Ken
    Riding, Rebecca L.
    Fan, Xueli
    Afshari, Khashayar
    Haddadi, Nazgol-Sadat
    McCauley, Sean M.
    Guney, Mehmet H.
    Luban, Jeremy
    Funakoshi, Takeru
    Yaguchi, Tomonori
    Kawakami, Yutaka
    Khvorova, Anastasia
    Fitzgerald, Katherine A.
    Harris, John E.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 218 (09):
  • [30] Global inhibition of HLA/LILR interactions by anti-MHC-I augments anti-tumor immunity
    Panda, Abir
    Natarajan, Kannan
    Sinha, Surajit
    Teke, Martha
    Jiang, Jiansheng
    Boyd, Lisa
    Hernandez, Jonathan
    Margulies, David
    Shevach, Ethan
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
12345